InvestorsHub Logo
Followers 469
Posts 23405
Boards Moderated 0
Alias Born 02/05/2004

Re: None

Monday, 07/27/2020 6:53:33 PM

Monday, July 27, 2020 6:53:33 PM

Post# of 307
A breakout is eminent with US Oncologic Drugs Advisory Committee advising the FDA to proceed with MESO’s GvHD treatment in August. MESO also received a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020, for RYONCIL (remestemcel-L) for steroid-refractory aGVHD

https://www.fool.com.au/2020/07/22/why-mesoblast-might-be-the-best-asx-healthcare-growth-share-to-own-right-now/



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MESO News